Cepheid Q1 Revenues Rise 24 Percent | GenomeWeb

NEW YORK (GenomeWeb News) — Cepheid said after the close of the market Thursday that its first quarter revenues grew 24 percent year over year, driven primarily by its commercial clinical business.

The Sunnyvale, Calif.-based molecular diagnostics firm reported total revenues of $132.6 million for the quarter ended March 31, up from $106.9 million in the comparable quarter a year ago, and beating average analyst estimates of $125.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.